Drug Profile
ALB 109564(a)
Alternative Names: 12'-methylthiovinblastine dihydrochloride; ALB109564(a)Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator AMRI
- Developer Curia
- Class Antineoplastics; Vinca alkaloids
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 07 Sep 2016 ALB 109564 (a) is still in phase I trials for Solid tumours in USA (Bessor Pharma pipeline, September 2016)
- 11 Feb 2013 ALB 109564(a) licensed to Chai Therapeutics worldwide